Yes, Humira (adalimumab) is an immunosuppressant. It works by blocking a specific protein in your immune system called TNF-alpha, which plays a central role in driving inflammation. By neutralizing this protein, Humira dials down immune activity enough to control autoimmune diseases, but that same suppression also reduces your body’s ability to fight certain infections. The FDA classifies it as a TNF blocker, and its prescribing label explicitly references its “immunosuppressive nature.”
How Humira Suppresses the Immune System
TNF-alpha is one of the most powerful alarm signals your immune system produces. When your body detects a threat, immune cells (mainly a type called macrophages) release TNF-alpha, which then triggers a cascade: it activates other immune cells, stimulates the release of additional inflammatory chemicals, and helps recruit white blood cells to the site of trouble. In autoimmune diseases, this process runs out of control and starts attacking healthy tissue.
Humira is a lab-made antibody that binds directly to TNF-alpha and prevents it from attaching to receptors on your cells. This blocks the downstream chain reaction, including activation of T-cells and B-cells, production of inflammatory signals like interleukin-1 and interleukin-6, and the expression of molecules that help immune cells stick to blood vessel walls and migrate into tissues. The result is a broad reduction in inflammatory activity, which is why it works across so many different conditions.
Conditions Humira Treats
The FDA has approved Humira for a wide range of autoimmune and inflammatory diseases: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, juvenile idiopathic arthritis, and uveitis (a type of eye inflammation). This unusually long list reflects how central TNF-alpha is to inflammation throughout the body. Each of these conditions involves the immune system mistakenly attacking healthy tissue, and blocking TNF-alpha helps interrupt that process regardless of where the inflammation occurs.
Infection Risk: The Main Trade-Off
Because Humira suppresses part of the immune system, it increases your vulnerability to infections. This is serious enough that the drug carries an FDA boxed warning about it. In a large safety analysis of nearly 30,000 patients across multiple clinical trials, serious infections occurred at a rate of 3.7 per 100 patient-years overall. The most common were pneumonia (0.6 per 100 patient-years) and cellulitis, a skin infection (0.2 per 100 patient-years). Rates varied by condition: patients with Crohn’s disease, ulcerative colitis, uveitis, and rheumatoid arthritis had the highest infection rates (3.5 to 6.9 per 100 patient-years), while those with psoriasis or ankylosing spondylitis had lower rates (around 1.0 to 1.8 per 100 patient-years).
Tuberculosis deserves special mention. TNF-alpha is critical for keeping dormant TB infections in check, so blocking it can allow latent TB to reactivate. The overall rate of serious TB in clinical trials was 0.2 per 100 patient-years. For this reason, you’ll be tested for latent TB before starting Humira. Hepatitis B screening is also required beforehand, since reactivation of that virus is another known risk.
Opportunistic infections (unusual infections that healthy immune systems easily handle) were rare in trials, occurring at less than 0.1 per 100 patient-years when TB and oral yeast infections were excluded.
Lymphoma and Cancer Risk
The FDA label also warns about a potential risk of certain cancers, particularly lymphoma. But the evidence on this is more nuanced than the warning might suggest. A meta-analysis found no increased relative risk of lymphoma with TNF-blocker monotherapy (meaning Humira used alone). The concern primarily applies when Humira is combined with another class of immune-suppressing drugs called thiopurines. In that combination, the lymphoma risk rises more meaningfully, with one study finding a six-fold increase compared to unexposed patients. Several studies that initially linked TNF blockers to lymphoma were later found to be confounded by patients’ prior or concurrent thiopurine use.
The absolute risk remains low even in higher-risk scenarios, and the medical consensus is that the benefits of controlling active autoimmune disease generally outweigh the cancer risk.
Common Side Effects
Beyond infection risk, the most frequent side effects are more mundane. In placebo-controlled trials for rheumatoid arthritis, 20% of patients on Humira experienced injection site reactions (redness, itching, pain, or swelling at the injection spot) compared to 14% on placebo. Upper respiratory infections affected 17% of patients versus 13% on placebo. Headache and rash each occurred in about 12% of patients. Sinusitis (11%), nausea (9%), and urinary tract infections (8%) were also common. Most of these overlap significantly with what placebo groups experienced, suggesting that not every cold or headache on Humira is caused by the drug itself.
Vaccines and Practical Precautions
One of the most practical ways Humira’s immunosuppressive effects show up in daily life is through vaccine restrictions. You can receive inactivated vaccines (like the flu shot) while on Humira, but live vaccines are off-limits. This includes the live shingles vaccine and certain travel vaccines. If you know you’ll need any live vaccines, the recommendation is to get them at least four weeks before starting treatment. For children, doctors recommend completing all routine immunizations before beginning Humira if possible.
If you were pregnant while on Humira, the drug can cross the placenta in the third trimester, which means your infant may also have a suppressed immune response for several months after birth. The safety of live vaccines in these exposed infants is not well established.
How It’s Taken
Humira is a self-injected medication given under the skin, typically every other week. It comes in pre-filled pens or syringes, so most people administer it at home after initial training. The standard dose for most conditions is 40 mg every two weeks, though some conditions like Crohn’s disease and ulcerative colitis start with higher loading doses before stepping down to the maintenance schedule.
Before your first injection, you’ll go through screening for TB and hepatitis B, and your doctor will review your vaccination history. These steps exist specifically because of Humira’s immunosuppressive effects, and they’re designed to catch and address vulnerabilities before the drug lowers your defenses.